Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

20172,090 citationsJournal Articlebronze Open Access

Authors

Rury R. Holman · Chinese University of Hong Kong

M. Angelyn Bethel · Chinese University of Hong Kong

Robert J. Mentz · Duke University

Vivian P. Thompson · Chinese University of Hong Kong

Yuliya Lokhnygina · Clinical Research Institute

John B. Buse · Oxford Centre for Diabetes, Endocrinology and Metabolism

Juliana C.N. Chan

Abstract

Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .).

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 13, pp. 1228-1239

DOI: 10.1056/nejmoa1612917

Field-Weighted Citation Impact: 151.66